PriceTargets.com logo

Prelude Therapeutics - PRLD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.75
  • Forecasted Upside: 400.00%
  • Number of Analysts: 4
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.95 As of 11/21/2024 11:25 AM ET
▼ -0.0117 (-1.22%)

This chart shows the closing price for PRLD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prelude Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRLD

Analyst Price Target is $4.75
▲ +400.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Prelude Therapeutics in the last 3 months. The average price target is $4.75, with a high forecast of $7.00 and a low forecast of $3.00. The average price target represents a 400.00% upside from the last price of $0.95.

This chart shows the closing price for PRLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Prelude Therapeutics. This rating has held steady since August 2024, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
10/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
9/19/2024HC WainwrightUpgradeHold ➝ Strong-Buy
9/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$7.00 ➝ $7.00
9/16/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
9/10/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
8/15/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
6/20/2024BarclaysDowngradeEqual Weight ➝ Underweight$3.00
3/13/2024JMP SecuritiesInitiated CoverageMkt Outperform$7.00
2/20/2024HC WainwrightDowngradeBuy ➝ Neutral$5.00
12/19/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$10.00 ➝ $4.00
11/7/2023HC WainwrightLower TargetBuy ➝ Buy$6.00 ➝ $5.00
10/19/2023HC WainwrightLower TargetBuy ➝ Buy$17.00 ➝ $6.00
8/17/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.00
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$10.00
8/4/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$7.00 ➝ $5.00
3/17/2023HC WainwrightBoost TargetBuy$15.00 ➝ $17.00
11/21/2022Bank of AmericaDowngradeNeutral ➝ Underperform$8.00 ➝ $6.00
11/17/2022HC WainwrightLower TargetBuy$16.00 ➝ $15.00
11/15/2022Morgan StanleyLower TargetEqual Weight$11.00 ➝ $10.00
9/9/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$19.00 ➝ $11.00
7/29/2022Jefferies Financial GroupInitiated CoverageBuy$9.00
5/12/2022HC WainwrightLower TargetBuy$62.00 ➝ $16.00
3/17/2022Morgan StanleyLower TargetOverweight$20.00 ➝ $19.00
3/15/2022Bank of AmericaDowngradeBuy ➝ Neutral$50.00 ➝ $10.00
2/28/2022BarclaysDowngradeOverweight ➝ Equal Weight$20.00 ➝ $12.00
11/17/2021BarclaysLower TargetOverweight$33.00 ➝ $20.00
11/15/2021HC WainwrightReiterated RatingBuy$61.00
10/8/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$60.00 ➝ $35.00
10/8/2021HC WainwrightReiterated RatingBuy$62.00
10/8/2021BarclaysLower TargetOverweight$80.00 ➝ $33.00
7/27/2021Bank of AmericaUpgradeNeutral ➝ Buy$60.00
4/26/2021HC WainwrightInitiated CoverageBuy$62.00
3/17/2021Morgan StanleyBoost TargetEqual Weight$47.00 ➝ $60.00
3/9/2021BarclaysInitiated CoverageOverweight$80.00
12/16/2020Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $47.00
11/20/2020Bank of AmericaDowngradeBuy ➝ Neutral
11/12/2020Morgan StanleyBoost TargetEqual Weight$34.00 ➝ $38.00
10/20/2020Bank of AmericaInitiated CoverageBuy$40.00
10/20/2020Morgan StanleyInitiated CoverageEqual Weight$34.00
10/20/2020The Goldman Sachs GroupInitiated CoverageNeutral$37.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Prelude Therapeutics logo
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Read More

Today's Range

Now: $0.95
Low: $0.95
High: $0.97

50 Day Range

MA: $1.80
Low: $0.94
High: $4.83

52 Week Range

Now: $0.95
Low: $0.93
High: $6.80

Volume

12,864 shs

Average Volume

162,831 shs

Market Capitalization

$52.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Prelude Therapeutics?

The following Wall Street research analysts have issued reports on Prelude Therapeutics in the last twelve months: Barclays PLC, HC Wainwright, JMP Securities, and Morgan Stanley.
View the latest analyst ratings for PRLD.

What is the current price target for Prelude Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Prelude Therapeutics in the last year. Their average twelve-month price target is $4.75, suggesting a possible upside of 393.9%. JMP Securities has the highest price target set, predicting PRLD will reach $7.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $3.00 for Prelude Therapeutics in the next year.
View the latest price targets for PRLD.

What is the current consensus analyst rating for Prelude Therapeutics?

Prelude Therapeutics currently has 2 sell ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PRLD, but not buy more shares or sell existing shares.
View the latest ratings for PRLD.

What other companies compete with Prelude Therapeutics?

Other companies that are similar to Prelude Therapeutics include Molecular Partners, Silence Therapeutics, SOPHiA GENETICS, MacroGenics and Inhibrx. Learn More about companies similar to Prelude Therapeutics.

How do I contact Prelude Therapeutics' investor relations team?

The company's listed phone number is 302-467-1280 and its investor relations email address is [email protected]. The official website for Prelude Therapeutics is www.preludetx.com. Learn More about contacing Prelude Therapeutics investor relations.